Your browser doesn't support javascript.
loading
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
Singhal, Ruchi; Rogers, Sherise C; Lee, Ji-Hyun; Ramnaraign, Brian; Sahin, Ilyas; Fabregas, Jesus C; Thomas, Ryan M; Hughes, Steven J; Nassour, Ibrahim; Hitchcock, Kathryn; Russell, Karen; Kayaleh, Omar; Turk, Anita; Zlotecki, Robert; DeRemer, David L; George, Thomas J.
  • Singhal R; Department of Medicine, University of Florida, Gainesville, FL, USA.
  • Rogers SC; Department of Medicine, Division of Hematology & Oncology, University of Florida, Gainesville, FL, USA.
  • Lee JH; Department of Biostatistics, University of Florida, Gainesville, FL, USA.
  • Ramnaraign B; Department of Medicine, Division of Hematology & Oncology, University of Florida, Gainesville, FL, USA.
  • Sahin I; Department of Medicine, Division of Hematology & Oncology, University of Florida, Gainesville, FL, USA.
  • Fabregas JC; Memorial Cancer Institute, Florida Atlantic University, Hollywood, FL, USA.
  • Thomas RM; Department of Surgery, University of Florida, Gainesville, FL, USA.
  • Hughes SJ; Department of Surgery, University of Florida, Gainesville, FL, USA.
  • Nassour I; Department of Surgery, University of Florida, Gainesville, FL, USA.
  • Hitchcock K; Tallahassee Memorial Hospital, Tallahassee, FL, USA.
  • Russell K; Tallahassee Memorial Hospital, Tallahassee, FL, USA.
  • Kayaleh O; Orlando Health Cancer Institute, Orlando, FL, USA.
  • Turk A; Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA.
  • Zlotecki R; Department of Radiation Oncology, University of Florida, Gainesville, FL, USA.
  • DeRemer DL; College of Pharmacy, University of Florida, Department of Pharmacotherapy & Translational Research, Gainesville, FL, USA.
  • George TJ; Department of Medicine, Division of Hematology & Oncology, University of Florida, Gainesville, FL, USA.
Future Oncol ; 19(27): 1841-1851, 2023 Sep.
Article en En | MEDLINE | ID: mdl-37753702
For patients with pancreatic cancer with little to no cancer near the blood vessels, the best life expectancy usually requires surgery and chemotherapy. FOLFIRINOX is a chemotherapy medicine that offers promising results for both patients getting surgery and for patients with widespread disease. However, it can cause harmful side effects. The side effects can be so bad that the chemotherapy has to be stopped or that surgery is no longer possible. In order to reduce the harmful side effects and improve outcomes, this investigation looks into the safety and practicality of using a different version of one of the medicines. The different version hopes to improve drug delivery and reduce harmful side effects. This regimen, NALIRIFOX, can be safer and more effective in patients awaiting surgery. Clinical Trial Registration: UF-STO-PANC-004 (NCT03483038) (ClinicalTrials.gov).
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Fármacos Sensibilizantes a Radiaciones / Adenocarcinoma Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Fármacos Sensibilizantes a Radiaciones / Adenocarcinoma Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article